<DOC>
	<DOCNO>NCT01369498</DOCNO>
	<brief_summary>This study evaluate efficacy safety simtuzumab ( GS-6624 ) bone marrow fibrosis either alone combination ruxolitinib participant Primary myelofibrosis ( PMF ) Post Polycythemia Vera Post Essential Thrombocythemia Myelofibrosis ( ET/PV MF ) . The study design two stage trial . In stage 1 , patient randomize two cohort receive either 200 700 mg study drug . In stage 2 , patient ruxolitinib randomize receive either 200 700 mg study drug .</brief_summary>
	<brief_title>Efficacy Safety Simtuzumab Adults With Primary , Post Polycythemia Vera Post Essential Thrombocythemia Myelofibrosis</brief_title>
	<detailed_description />
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<criteria>Must diagnose PMF post ET/PV MF intermediate1 , intermediate2 high risk disease accord IWG prognostic scoring system , low risk disease symptomatic splenomegaly ≥ 10 cm leave costal margin physical exam . Must adequate organ function demonstrate follow : ALT ( SGPT ) and/or AST ( SGOT ) ≤ 2.5x upper limit normal ( ULN ) , ≤ 4x ULN ( upon judgment treat physician , believe due extramedullary hematopoiesis [ EMH ] related MF ) ; Direct bilirubin ≤ 1.5 x ULN ; ≤ 2x ULN ( upon judgment treat physician , believe due extramedullary hematopoiesis [ EMH ] related MF ) ; Serum creatinine ≤ 2.5 mg/dL . 2.5 mg/dL . In Stage 2 , subject must ruxolitinib least 8 week stable dose least 4 week . ECOG performance status ( PS ) ≤ 2 Treatmentrelated toxicity prior therapy must resolve Grade ≤ 1 Women childbearing potential men must agree use one medically approve ( ie , mechanical pharmacological ) contraceptive measure partner agree additional barrier method contraception duration study 90 day last administration study drug . Please refer Section 11 definition female child bear potential list acceptable contraceptive method study . Any serious medical condition psychiatric illness would prevent , ( judge treat physician ) subject signing informed consent form condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study . Pregnant lactating . Known history human immunodeficiency virus ( HIV ) , hepatitis C , hepatitis B . History presence form cancer within 3 year prior enrollment , exception excise basal cell squamous cell carcinoma skin , cervical carcinoma situ breast carcinoma situ excise resect completely without evidence local recurrence metastasis . Participation investigational drug device trial within 2 week prior study Day 1 within 5 time halflife investigational agent clinical study , know . Use cytotoxic chemotherapeutic agent ( eg , hydroxyurea ) , corticosteroid ( prednisone ≤ 10 mg/day corticosteroid equivalent allow ) , immune modulators ( eg , thalidomide ) within 2 week interferon use within 4 week prior study Day 1 . Symptomatic congestive heart failure ( New York Heart Association Classification &gt; Class II ) , unstable angina , unstable cardiac arrhythmia require medication . History surgery within 2 week prior enrollment anticipate surgery study period . Any condition might reduce chance obtain data require protocol might compromise ability give truly informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Hematology</keyword>
	<keyword>Myelofibrosis</keyword>
	<keyword>Thrombocythemia Myelofibrosis</keyword>
	<keyword>Bone Marrow Diseases</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Blood Diseases</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Blood Disorders</keyword>
</DOC>